GLP-1semaglutidedpp-4 inhibitorshfpefcognition

Study compares oral semaglutide and DPP-4 inhibitors on cognition in HFpEF

The Internal and Emergency Medicine paper looks at older patients with obesity and heart failure with preserved ejection fraction.

By Maren Holt · Senior Reporter, GLP-1

Sep 25 20:00 ETSource: Internal and emergency medicine

The wire

01Researchers report in Internal and Emergency Medicine on cognitive impairment risk with oral semaglutide versus DPP-4 inhibitors in elderly patients with HFpEF and obesity.
02Clinicians managing HFpEF patients on incretin therapy have little comparative data on cognitive outcomes, an endpoint rarely addressed in glucose-lowering drug selection.
03Full methods, cohort size and effect estimates were not detailed in the material at hand; comparative observational work of this kind carries confounding by indication.

From the source

Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity
Internal and emergency medicine · 2026 Sep 26 · Ayyaz F, Khan H, Zia I et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42799976/